| 000 | 00979 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517001008.0 | ||
| 264 | 0 | _c20150626 | |
| 008 | 201506s 0 0 eng d | ||
| 022 | _a1873-4286 | ||
| 024 | 7 |
_a10.2174/1381612820666140826153347 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGlavan, Tanja Matijevic | |
| 245 | 0 | 0 |
_aThe exploitation of Toll-like receptor 3 signaling in cancer therapy. _h[electronic resource] |
| 260 |
_bCurrent pharmaceutical design _c2014 |
||
| 300 |
_a6555-64 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aToll-Like Receptor 3 _xagonists |
| 700 | 1 | _aPavelic, Jasminka | |
| 773 | 0 |
_tCurrent pharmaceutical design _gvol. 20 _gno. 42 _gp. 6555-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1381612820666140826153347 _zAvailable from publisher's website |
| 999 |
_c24302893 _d24302893 |
||